SCHEMBL8203933

SCHEMBL8203933

Clc1cc2c(cc1Cl)Nc1ccccc1C(N1CCN(Cc3ccc4c(c3)OCO4)CC1)=N2

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 9/20 0.74
DRD1 P21728 9/20 0.74
ALDH1A1 P00352 3/20 0.53
DRD3 P35462 3/20 0.51
DRD5 P21918 2/20 0.51
HRH1 P35367 2/20 0.51
HRH3 Q9Y5N1 2/20 0.51
HRH4 Q9H3N8 2/20 0.50
MEN1 O00255 2/20 0.49
CYP1A2 P05177 2/20 0.49
CYP3A4 P08684 2/20 0.49
HTR1A P08908 2/20 0.49
ADRA2A P08913 2/20 0.49
CYP2D6 P10635 2/20 0.49
ADRA2B P18089 2/20 0.49
ADRA2C P18825 2/20 0.49
NFKB1 P19838 2/20 0.49
SLC6A2 P23975 2/20 0.49
MAPK1 P28482 2/20 0.49
SLC6A4 P31645 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8196479 0.91 DRD2 (0.69) DRD2DRD1ALDH1A1DRD3DRD5
SCHEMBL29623704 0.91 DRD2 (0.90) DRD2DRD1ALDH1A1DRD3DRD5
SCHEMBL8203911 0.89 DRD2 (0.75) DRD2DRD1ALDH1A1DRD3DRD5
SCHEMBL8204038 0.89 DRD2 (0.69) DRD2DRD1ALDH1A1DRD3DRD5
SCHEMBL8204496 0.85 DRD2 (0.77) DRD2DRD1ALDH1A1DRD3DRD5
SCHEMBL8203868 0.84 DRD2 (0.76) DRD2DRD1ALDH1A1DRD3DRD5
SCHEMBL8202569 0.84 DRD1 (0.64) DRD2DRD1ALDH1A1DRD3DRD5
SCHEMBL9050759 0.82 DRD2 (0.62) DRD2DRD1ALDH1A1DRD3MEN1
SCHEMBL8204077 0.79 CHRM1 (0.64) DRD2DRD1ALDH1A1DRD3DRD5
SCHEMBL8202579 0.79 DRD2 (0.61) DRD2DRD1ALDH1A1DRD3MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6103715-A COMPOUNDS THAT BIND TO THE DOPAMINE D4 RECEPTOR AND THEIR USE AS ANXIOLYTIC AGENTS, TREATMENT FOR SCHIZOPHRENIA, AND DRUG SCREENING; SIDE EFFECT REDUCTIOON ALLELIX BIOPHARMACEUTICALS INC. (CA) 2000-08-15 US disclosed
EP-0736024-A1 N-HETEROBICYCLYL-PIPERAZINYL OR-PIPERADINYL TRICYCLIC DERIVATIVES USEFUL AS DOPAMINE RECEPTOR LIGANDS Allelix Biopharmaceuticals Inc. (CA) 1996-10-09 EP disclosed
US-5538965-A TREATMENT OF PSYCHOLOGICAL DISORDERS SUCH AS SCHIZOPHRENIA AND ANXIETY ALLELIX BIOPHARMACEUTICALS INC. (CA) 1996-07-23 US disclosed
WO-1995017400-A1 N-HETEROBICYCLYL-PIPERAZINYL OR-PIPERADINYL TRICYCLIC DERIVATIVES USEFUL AS DOPAMINE RECEPTOR LIGANDS ALLELIX BIOPHARMACEUTICALS INC. (CA) 1995-06-29 WO disclosed